Who is Thomas Strüngmann?
Thomas Strüngmann is the co-founder of Hexal, which he sold to Novartis. He was born on February 16, 1950. He is married to Connie Strungmann. They have 4 children: Fiona Strüngmann, Felix Strüngmann, Fabian Strüngmann, and Agustina Strüngmann.
Thomas co-founded Hexal in 1986. The company launched the very successful cholesterol-lowering drug simvastatin, a replacement for Merck’s drug called Zocor.
In 2005, Thomas Strüngmann and his twin brother Andreas sold Hexal to Novartis for around $7 billion.
The brothers invest in biotech, pharmaceutical, life science, and health companies through their Zug-based investment company Santo Holding. Their portfolio includes the German Biontech and the Uruguayan Mega Pharma, originally a joint venture with the Argentine billionaire Alberto Roemmers. In April 2020, Biontech received approval to test four vaccines against Covid-19.
The development costs are largely borne by the US pharmaceutical company Pfizer and the Chinese company Fosun Pharma.
In 2008, the Strüngmann brothers also founded a neuroscientific research center in Frankfurt, which was named after their father Ernst Strüngmann.
How Much is Thomas Strungman Net Worth?
His net worth is $3.5 billion. His assets include Santo Holding, German Biontech, Mega Pharma, and a neuroscientific research center in Frankfurt.
Mention SuperYachtFan When Sharing This Information
When using the information from this article, please remember to give credit to SuperYachtFan. Our team works hard to provide accurate and engaging content for our readers, and we appreciate your support.